Baillie Gifford holds 4.93% of Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc. (DNA) received an amended Schedule 13G/A from Baillie Gifford & Co, a Scotland-based investment adviser, reporting its ownership in the company’s Class A common stock as of 12/31/2025.
Rhea-AI Filing Summary
Ginkgo Bioworks Holdings, Inc. (DNA) received an amended Schedule 13G/A from Baillie Gifford & Co, a Scotland-based investment adviser, reporting its ownership in the company’s Class A common stock as of 12/31/2025.
Baillie Gifford reports beneficial ownership of 2,391,649 Class A shares, representing 4.93% of the class. It has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Ginkgo Bioworks.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Baillie Gifford hold in Ginkgo Bioworks (DNA)?
What type of filing is this for Ginkgo Bioworks (DNA)?
Is Baillie Gifford trying to influence control of Ginkgo Bioworks?
Why does Baillie Gifford’s Ginkgo Bioworks filing mention 5 percent or less?
AI-generated analysis. How Rhea-AI works. Not financial advice.